MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

MoonLake Immunotherapeutics (MLTX) shares surged 18% following a report that Merck (MRK) made a non-binding buyout offer earlier this year valuing the company at over $3 billion, though the offer was reportedly rejected. Merck's interest in MoonLake, which is developing sonelokimab for inflammatory diseases, is driven by a desire to diversify its revenue stream amid concerns over Keytruda's future exclusivity. This potential acquisition aligns with a broader trend of Big Pharma pursuing strategic assets in immunology and oncology, as evidenced by Sanofi's $9.5 billion acquisition of Blueprint Medicines.

Analysis

MoonLake Immunotherapeutics (MLTX) shares surged 18% following a Financial Times report that Merck (MRK) submitted a non-binding acquisition offer earlier this year, valuing MLTX at over $3 billion. Although this initial offer was reportedly rejected and both companies have declined to comment, the development signals significant M&A interest in the clinical-stage biotech, with the potential for revived negotiations or alternative suitors. MoonLake's primary asset, sonelokimab, a novel nanobody therapy in late-stage studies for inflammatory diseases like hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), with topline HS data anticipated around September 2025, aligns with Merck's strategic imperative to diversify its revenue streams. This urgency for Merck stems from its heavy reliance on Keytruda, which accounted for nearly 46% of its 2024 revenues and faces loss of exclusivity post-2028. The reported pursuit of MoonLake is consistent with a broader pharmaceutical industry trend where large companies are actively acquiring strategic assets in high-growth areas such as immunology and oncology, exemplified by Sanofi's $9.5 billion acquisition of Blueprint Medicines and Bristol Myers Squibb's co-development agreement with BioNTech. Despite this M&A-driven rally, MLTX's stock remains down 10% year-to-date, contrasting with the industry's 4% decline, underscoring the speculative nature of the current situation, which is reflected in the overall strongly positive sentiment (score 0.65) and high market impact (score 0.7) despite the speculative tone of the news.

Key Decisions for Investors

• Investors holding MoonLake Immunotherapeutics (MLTX) should weigh the 18% gain against the potential for a revised or competing acquisition offer, while also considering the clinical catalyst of sonelokimab's HS data expected around September 2025 should a deal not materialize.
• For Merck (MRK) shareholders, this reported interest in MLTX, even if initially rebuffed, reinforces the company's proactive stance on mitigating revenue concentration risk from Keytruda; continued monitoring of MRK's M&A and licensing activities is warranted.